• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

42.37 -0.59 (-1.37%)
Streaming Delayed Price Updated: 10:03 AM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CG Oncology, Inc. - Common stock

< Previous 1 2 Next >
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
September 05, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Completes Enrollment in PIVOT-006
September 03, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
August 29, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 08, 2025
From CG Oncology Inc.
Via GlobeNewswire
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
July 29, 2025
From CG Oncology Inc.
Via GlobeNewswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
July 07, 2025
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
July 07, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
June 18, 2025
Issued on behalf of Oncolytics Biotech Inc. Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer.... 
Via FinancialNewsMedia
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 05, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
May 15, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
May 13, 2025
From CG Oncology Inc.
Via GlobeNewswire
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
May 01, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
April 26, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
April 24, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
March 31, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
March 28, 2025
From CG Oncology Inc.
Via GlobeNewswire
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
March 24, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
March 12, 2025
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Pricing of Public Offering
December 12, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Proposed Public Offering
December 11, 2024
From CG Oncology Inc.
Via GlobeNewswire
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 06, 2024
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC 
From CG Oncology Inc.
Via GlobeNewswire
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From CG Oncology Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  243.62
-1.02 (-0.42%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap